On 28 September 2026, the Council of the European Union approved the new Pharma Package, marking an important milestone in the reform of European pharmaceutical legislation, more than twenty years after the last major overhaul.
The reform introduces significant changes aimed at reshaping the regulatory framework for the European pharmaceutical sector, addressing the evolving needs of the healthcare system and emerging challenges.
SCF presents an in-depth analysis of the key changes introduced by the Pharma Package, examining its main provisions and providing an overview of the most relevant developments for the sector: Pharma Package | Key Changes
